- Home
- GECC vs MREO Comparison
GECC vs MREO Comparison
Compare GECC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | MREO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.0M | 67.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GECC | MREO |
|---|---|---|
| Price | $5.01 | $0.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $10.75 | $1.50 |
| AVG Volume (30 Days) | 144.6K | ★ 1.4M |
| Earning Date | 03-02-2026 | 03-19-2026 |
| Dividend Yield | ★ 24.14% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $0.92 | $6,756.00 |
| Revenue Next Year | N/A | $38.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $0.20 |
| 52 Week High | $11.45 | $2.94 |
Technical Indicators
Market Signals| Indicator | GECC | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 33.58 | 38.00 |
| Support Level | $4.63 | $0.35 |
| Resistance Level | $7.07 | $0.42 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 34.25 | 32.16 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).